Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Authors: Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah Jean Lee Wong, Douglas R. Adkins, Paul Swiecicki, Wanxing Chai‐Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, Mónica V. Estrada, Kathryn A. Gold, Gregory A. Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E.W. Cohen - The Lancet 2021 cited by 258